Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Adam R Glassman, Danni Liu, Lee M Jampol, Jennifer K Sun, Diabetic Retinopathy Clinical Research Network, Adam R Glassman, Danni Liu, Lee M Jampol, Jennifer K Sun, Diabetic Retinopathy Clinical Research Network
Abstract
Purpose: To compare blood pressure and urine albumin-creatinine ratio over time for participants receiving aflibercept, bevacizumab, or ranibizumab.
Methods: Preplanned secondary analyses from a randomized trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME). The Diabetic Retinopathy Clinical Research Network (DRCR.net) enrolled 660 participants with DME and visual acuity 20/32 or worse in at least one eye. Eyes received intravitreous injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab based on a structured retreatment protocol over 2 years. Main outcome measures were (1) a change in blood pressure at 2 years, and (2) a change in urine albumin-creatinine ratio (UACR) at 1 year.
Results: At baseline, 95 participants (14%) had normal blood pressure, 220 (33%) had borderline blood pressure elevation, 206 (31%) had mild blood pressure elevation, and 139 (21%) had moderate blood pressure elevation. Average change in mean arterial pressure from baseline to 2 years was -1.2 ± 15, -1.8 ± 13.5, -2.6 ± 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69). At baseline 247 participants (38%) had no albuminuria (<30 mg/g), 195 (30%) had microalbuminuria (30-300 mg/g), and 212 (32%) had macroalbuminuria (>300 mg/g). Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).
Conclusions: There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab.
Figures
References
- Wells JA, Glassman AR, Ayala AR, et al.; for the Diabetic Retinopathy Clinical Research Network. . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372: 1193– 1203.
- Elman MJ, Aiello LP, Beck RW,et al. for the Diabetic Retinopathy Clinical Research Network. . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117: 1064– 1077.e35.
- Nguyen QD, Brown DM, Marcus DM,et al. . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119: 789– 801.
- Nguyen QD, Shah SM, Khwaja AA,et al. . Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117: 2146– 2151.
- Mitchell P, Bandello F, Schmidt-Erfurth U,et al. . The RESTORE study ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118: 615– 625.
- Ranpura V, Hapani S, Chuang J, Wu S. . Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010; 49: 287– 297.
- Gross JG, Glassman AR, Klein MJ,et al. . Interim safety data comparing ranibizumab with panretinal photocoagulation among participants with proliferative diabetic retinopathy. JAMA Ophthalmol. 2017; 135: 672– 673.
- Avery RL, Gordon GM. . Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016; 134: 21– 29.
- Ying GS, Maguire MG, Daniel E,et al. . Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015; 122: 2523– 2531.e1.
- Chakravarthy U, Harding SP, Rogers CA,et al. for the IVAN Study Investigators. . Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119: 1399– 1411.
- Wells JA, Glassman AR, Ayala AR,et al. . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016; 123: 1351– 1359.
- American Heart Association. The facts about high blood pressure. Available at: . Accessed April 24, 2017.
- National Institute of Diabetes and Digestive and Kidney Diseases. Quick reference on UACR and GFR: in evaluating patients with diabetes for kidney disease. Available at: . Accessed June 6, 2017.
- Afkarian M, Zelnick LR, Hall YN,et al. . Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016; 316: 602– 610.
- Cruickshanks KJ, Ritter LL, Klein R, Moss SE. . The association of microalbuminuria with diabetic retinopathy: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology. 1993; 100: 862– 867.
- Sun JK, Keenan HA, Cavallerano JD,et al. . Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care. 2011; 34: 968– 974.
- Brown DM, Schmidt-Erfurth U, Do DV,et al. . Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015; 122: 2044– 2052.
Source: PubMed